Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Original ArticlesMineral Metabolism/Bone Disease
You have accessRestricted Access

Parathyroidectomy and Heart Rate Variability in Patients with Stage 5 CKD

Jing Zhang, Xiangbao Yu, Bin Sun, Jianling Bai, Yongyue Wei, Xiaoming Zha, Yiyao Cui, Ming Zeng, Jingjing Zhang, Jia Liu, Huijuan Mao, Bo Zhang, Haibin Ren, Yifei Ge, Xueqiang Xu, Zhixiang Shen, Changying Xing, Kejiang Cao and Ningning Wang
CJASN August 2013, 8 (8) 1378-1387; DOI: https://doi.org/10.2215/CJN.10381012
Jing Zhang
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiangbao Yu
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bin Sun
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianling Bai
†Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongyue Wei
†Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoming Zha
‡General Surgery, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiyao Cui
‡General Surgery, and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming Zeng
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingjing Zhang
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jia Liu
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huijuan Mao
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Zhang
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haibin Ren
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yifei Ge
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xueqiang Xu
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhixiang Shen
§Department of Nephrology, Jiangsu Province Geriatric Hospital, Nanjing, People’s Republic of China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Changying Xing
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kejiang Cao
‖Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ningning Wang
Departments of *Nephrology,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Summary

Background and objectives Lower heart rate variability implies increased risk of cardiovascular disease. This study aimed to evaluate the relationship between mineral metabolism and heart rate variability and longitudinal changes of heart rate variability after parathyroidectomy in stage 5 CKD patients.

Design, setting, participants, & measurements This cross-sectional study included 118 stage 5 CKD patients, 87 controls, and a prospective study in two subgroups classified as successful (n=17) and unsuccessful (n=4) parathyroidectomy follow-up enrolled from March of 2011 to December of 2012. Blood examination and 24-hour Holter for heart rate variability were measured.

Results Most heart rate variability indices were lower in stage 5 CKD patients. In multivariate stepwise regression models, serum intact parathyroid hormone was correlated with mean normal-to-normal R–R intervals, mean heart rate, and very low frequency, serum calcium was correlated with SD of 5-minute average of normal R–R intervals, and serum phosphorus was correlated with very low frequency and low frequency/high frequency. Compared with baseline, the successful parathyroidectomy subgroup had significant improvements in mean normal-to-normal R–R intervals, mean heart rate, SD of normal-to-normal R–R intervals, SD of 5-minute average of normal R–R intervals, very low frequency, high frequency, and low frequency/high frequency. There was no significant change of heart rate variability in patients after unsuccessful parathyroidectomy.

Conclusions Disorders of mineral metabolism are associated with decreased heart rate variability in stage 5 CKD. Successful parathyroidectomy may contribute to reverse this cardiovascular disease risk in severe secondary hyperparathyroidism patients.

Introduction

Cardiovascular disease (CVD) is a leading cause of mortality and accounts for 39% of overall deaths in ESRD (1). The ability to identify patients at risk for death and prescribe therapy to reduce CVD risk is of considerable significance in the care of patients with ESRD.

Secondary hyperparathyroidism (SHPT) is universal in ESRD patients and characterized by derangement of calcium/phosphate homeostasis, elevated levels of parathyroid hormone (PTH), and hyperplastic parathyroid gland (PTG) (2–4). These patients present with various bone disorders and high risk of cardiovascular morbidity and mortality (5–8). Recent studies have shown the possibility that parathyroidectomy (PTX) can reduce the risk of CVD (9–12).

In the last decade, heart rate variability (HRV) has emerged as a powerful, noninvasive clinical tool for the assessment of sympathetic and parasympathetic control of the heart using standard electrocardiographic monitoring. Lower HRV has a significant predictive value for various CVDs, such as ventricular arrhythmias and sudden death (13–16).

Previous studies have shown a marked reduction of HRV indices in ESRD patients (17–20). To our knowledge, few studies have evaluated the correlation between SHPT and HRV in ESRD patients. Thus, the present study aimed to examine the associations of mineral metabolism with HRV indices in stage 5 CKD patients and investigate longitudinal changes of HRV in two subgroups with successful and unsuccessful PTX affected by severe SHPT.

Materials and Methods

Patients

We investigated 118 stable stage 5 CKD patients ages 20–75 years. Patients had an estimated GFR<15 ml/min per 1.73 m2 while awaiting commencement of dialysis or on maintenance dialysis (either hemodialysis or peritoneal dialysis). Hemodialysis treatment was performed for 12 hours weekly using bicarbonate as dialysate. Thirty-seven severe SHPT patients who underwent total PTX with forearm autotransplantation were enrolled. PTX was performed in patients with severe hyperparathyroidism (persistent serum levels of intact PTH [iPTH]>800 pg/ml [88.0 pmol/L]) associated with hypercalcemia and/or hyperphosphatemia according to the Kidney Disease Outcomes Quality Initiative guideline (21). Patients with PTX were refractory to medical therapy, including dietary phosphate restriction, low calcium dialysis, calcium-based phosphate binders, and oral calcitriol (3.0–7.0 µg), per hemodialysis for 3–5 months (21). Because vitamin D analogs and calcimimetics were unavailable in mainland China during the study period, none of the patients took these two drugs. Successful PTX was defined as normalization of serum calcium (Ca), phosphorus (P), and alkaline phosphatase (ALP) and maintenance of no more than two to three times serum iPTH compared with normal (ranging from 10 to 88 pg/ml). Because the PTX patients were derived from a wide geographical area, some of them dropped out after the operation because of transference to other dialysis units, inability to contact, or poor compliance. After ≥3 months after the surgery, 17 patients who underwent successful PTX were then subsequently followed up (median of 5.0 months). Four patients who underwent unsuccessful PTX were followed up for a median of 2.3 months. They were difficult to observe for a long period of time because of their strong desire for reoperation.

Participants were excluded if they had experienced episodes of acute myocardial infarction, stroke, a major surgical procedure within the past 2 months (15), malignant neoplasm, or any psychiatric diagnosis during the past 5 years (22,23) and suffered from severe congenital heart disease, atrial fibrillation or flutter, high-grade heart block, permanent pacemaker implantation, severe hepatic disease, chronic obstructive lung disease (24), or neurologic deficit (e.g., spinal cord injury or peripheral nerve trauma). We also excluded participants who were pregnant or had any infection, fever, other problems limiting their normal daily activities, or fasting blood glucose on the day of evaluation greater than 200 mg/dl, because they can decrease nerve conduction velocity and distort the results of autonomic testing (25).

Control Group

To compare HRV between stage 5 CKD patients and healthy individuals, we recruited 87 controls matched for age and sex. Exclusion criteria were the same as for the patients studied but also included any known renal disease.

Protocols

At enrollment, 5 ml venous whole blood was drawn after an overnight fast. Each participant underwent a 24-hour Holter monitoring within 1 week to allow assessment of baseline features. For hemodialysis patients, blood samples were collected before dialysis, and HRV was analyzed on a nondialysis day. For severe SHPT patients who underwent PTX, these studies were performed no more than 2 weeks before surgery. Patients were subsequently followed up after PTX, and examinations of laboratory value and HRV were repeated. Clinical characteristics, medical history, and use of medications were strictly recorded.

Between March of 2011 and December of 2012, all patients and controls gave informed consent, and the study protocols were approved by the Research Ethics Committee of The First Affiliated Hospital of Nanjing Medical University, People’s Republic of China.

Analysis of Laboratory Values

Blood routine tests were performed using an LH-750 Hematology Analyzer (Beckman Coulter, Inc., Fullerton, CA). Biochemical indices, such as serum albumin (Alb), lipid profile, Ca, P, and ALP, were measured using an Automatic Biochemical Analyzer (AU5400; Olympus Corporation, Tokyo, Japan). Serum iPTH levels were measured using a UniCel DxI800 Access Immunoassay System (Beckman Coulter, Inc., Fullerton, CA).

Analysis of HRV

Holter electrocardiogram was digitized to 12-bit data at 128 Hz with a scanner (MARS-PC; GE Company, Fairfield, CT) on which QRS complexes were collected automatically. The results were reviewed, and any errors in QRS labeling were edited manually. Computations of HRV measurements were performed using custom-made Marquetter analytical software.

Time domain variables included mean normal-to-normal R–R intervals (mean NN), SD of the normal-to-normal R–R intervals (SDNN), SD of 5-minute average of normal R–R intervals (SDANN), root mean square of differences between adjacent normal R–R intervals (rMSSD), and proportion of adjacent R–R intervals differing by >50 ms over 24 hours (pNN50%). For frequency domain analysis, the power spectrum was quantified by fast Fourier transformation for the following frequency bands: 0.0033 to <0.04 Hz (very low frequency [VLF]), 0.04 to <0.15 Hz (low frequency [LF]), and 0.15–0.4 Hz (high frequency [HF]). LF/HF was also calculated. Frequency domain measurements of HRV were transformed to natural logarithms, because their distributions were skewed (26).

Statistical Analyses

Categorical variables were presented as number and proportion, and continuous variables were presented as mean ± SD or median (interquartile range). Differences between groups were compared using independent samples t or Wilcoxon rank sum test for continuous variables and chi-squared or Fisher exact test for categorical variables. Baseline serum iPTH levels were transformed to natural logarithms, because they were not normally distributed. Multiple stepwise regression models were established, and they were nonadjusted and adjusted for iPTH to identify factors affecting 24-hour HRV parameters. A paired sample t test was used to assess the differences between values recorded before and after PTX. P<0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 17.0 (SPSS Inc., Chicago, IL).

Results

Patients Characteristics

We divided all stage 5 CKD patients (n=118) into a non-PTX group (n=81) and a PTX group (n=37). The latter included a nonfollow-up group (n=16), a successful PTX follow-up group (n=17), and an unsuccessful PTX follow-up group (n=4). Clinical characteristics and laboratory results in stage 5 CKD patients and healthy controls (n=87) were shown in Table 1. Stage 5 CKD patients had lower body mass index, hemoglobin (Hb), hematocrit (Hct), HDL, total cholesterol, and Alb. Prevalent disorders in mineral metabolism, especially serum P, ALP, and iPTH abnormality, were observed in stage 5 CKD patients (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Clinical characteristics and laboratory results

Baseline Values and Determinants of HRV

As presented in Table 2, baseline HRV analysis in stage 5 CKD patients showed lower time and frequency domains than controls, except for HF. There were no statistically significant differences in baseline HRV parameters between the successful PTX follow-up group (n=17) and the nonfollow-up group (n=16). Variables including demographics (age, sex, body mass index, dialysis vintage, systolic pressure, and diastolic pressure), laboratory values (Hb, Hct, glucose, Alb, and triglyceride), and bone metabolism panel (Ca, P, ALP, and iPTH) were selected as independent variables in the multivariable models (Table 3). Taking all HRV indices as dependent variables, we observed a powerful association between mineral metabolism and HRV indices. Serum iPTH was independently correlated with mean NN, mean HR, and VLF. Serum Ca was independently correlated with SDANN, and serum P was independently correlated with VLF and LF/HF. The results remained significant after the adjustment for iPTH (data not shown).

View this table:
  • View inline
  • View popup
Table 2.

Baseline heart rate variability parameters of study groups

View this table:
  • View inline
  • View popup
Table 3.

Multiple stepwise regression models predicting 24-hour heart rate variability parameters (n=118)

Baseline Information of Severe SHPT Patients with Successful PTX

PTX patients (n=37) tended to be younger, have longer dialysis vintage, and have a lower rate of diabetic mellitus than the non-PTX patients (n=81). Some PTX patients with severe anemia or hypoalbuminemia needed correction by blood transfusion or albumin infusion for preoperative preparation. Therefore, PTX patients (n=37) had higher baseline levels of serum Hb, Hct, and Alb compared with non-PTX patients (n=81). No significant differences were shown in laboratory results between the nonfollow-up group (n=16) and the successful PTX follow-up group (n=17).

Average age of successful PTX follow-up cohort (n=17) at baseline was 48.8±12.1 years. The mean duration of dialysis was 91.8 months. Thirteen patients were hypertensive, and one patient had both diabetes mellitus and coronary heart disease (Table 1).

Follow-Up Study of Laboratory Values in Successful PTX Patients

The pre- and postoperative serum indices of laboratory values are shown in Figure 1. Duration of follow-up was different in successful PTX patients, but the postoperative mineral metabolism indices were controlled at a satisfactory level, and no time trend was observed (data not shown). Serum iPTH levels were significantly lower (from 1717.8 [1350.8–3209.7] to 72.4 [42.7–242.5] pg/ml, P<0.001), and serum P levels were significantly decreased (from 6.9±1.8 to 2.9±1.5 mg/dl, P<0.001). There was also significant downregulation of serum Ca levels (10.5±0.6 versus 8.9±1.0 mg/dl, P<0.001) and serum ALP levels (527.3 [228.3–1006.8] versus 169.9 [111.0–244.8] μ/L, P<0.001). These results indicated a correction status of mineral metabolism in severe SHPT patients after total PTX with forearm transplantation. A significant increase in serum Alb levels (38.8±4.8 versus 41.9±3.7 g/L, P<0.05) was also observed in these patients.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Comparison of laboratory values in severe SHPT patients before and after successful PTX. Serum levels of (A) iPTH, (B) P, (C) Ca, (D) ALP, (E) Alb, and (F) Hb pre- and postoperative. Data are mean ± SD (n=17). §P<0.05, *P<0.001. Alb, albumin; ALP, alkaline phosphatase; Ca, calcium; Hb, hemoglobin; iPTH, intact parathyroid hormone; P, phosphorus; PTX, parathyroidectomy; SHPT, secondary hyperparathyroidism.

Improvements of Decreased HRV in Successful PTX Patients

As presented in Table 4, we observed significant improvements in HRV parameters in severe SHPT patients after successful PTX. These parameters included mean 24-hour HR (76.8±8.1 versus 87.1±10.7 beats/min, P<0.001), mean NN (790.9±83.0 versus 699.7±91.5 ms, P<0.001), SDNN (84.2±28.6 versus 67.8±24.6 ms, P=0.003), SDANN (73.3±29.7 versus 57.9±25.4 ms, P=0.004), VLF (5.9±0.7 versus 5.4±0.9 [ln(ms2)], P=0.008), HF (1.7±2.8 versus 3.4±1.1 [ln(ms2)], P=0.02), and LF/HF (2.0±1.4 versus 1.0±0.8, P=0.008; all relative to baseline).

View this table:
  • View inline
  • View popup
Table 4.

Heart rate variability in severe secondary hyperparathyroidism patients before and after parathyroidectomy

Changes of HRV in Unsuccessful PTX Patients

Four SHPT patients who underwent unsuccessful PTX showed no statistical significance in pre- and postoperative serum levels of iPTH (1639.9 [1491.3–2908.1] versus 1122.0 [911.2–2819.6] pg/ml, P=0.07), Ca (10.4±1.0 versus 9.8±1.8 mg/dl, P=0.50), and P (6.2±1.6 versus 5.4±1.8 mg/dl, P=0.18) in a median follow-up period of 2.3 months.

Average age of these patients at baseline was 44.5±8.9 years. The mean duration of dialysis was 106.3 months. One patient was hypertensive and had diabetes mellitus.

No statistically significant changes in HRV indices were observed in these patients before and after unsuccessful PTX (Table 4).

Discussion

In the last decade, decreased HRV has been established as a significant independent risk factor for higher mortality and cardiac death (15,16,27). It seemed to be caused by impairment of the cardiovascular autonomic control characterized by withdrawal in parasympathetic modulation and predominance in sympathetic tone (28). As in previous studies (17–20,29–33), our results showed that stage 5 CKD patients exhibited a marked reduction in HRV indices relative to age- and sex-matched controls, indicating that sympathetic hyperactivity may play an important role in increasing the risk of CVD among ESRD patients.

It has been proposed that CKD–mineral and bone disorder may be caused by disordered mineral metabolism (34,35), which is common among patients with stage 5 CKD and has been also detected in patients with stages 3 and 4 CKD (36). CVD, fractures, and mortality are its major outcomes. Increased PTH may diminish cardiac contractility, induce ventricular hypertrophy (37,38), and enhance coronary risk (39) and cardiovascular calcification (40,41). PTH also plays a role in disturbances in the autonomic nervous system—both sympathetic and parasympathetic. Wanic-Kossowska et al. (42) reported correlations between serum iPTH levels and SDNN, pNN50%, and rMSSD in 59 hemodialysis patients. Polak et al. (43) observed negative correlations between serum iPTH and both LF and HF. They also found total spectral power to be lower in patients with high serum levels of iPTH, which indicated deterioration in total autonomic activity. Here, we confirmed that disordered mineral metabolism, especially serum levels of iPTH, Ca, and P, was significantly associated with decreased HRV indices (Table 3). These results revealed that dysregulation in cardiovascular autonomic control raised by abnormal mineral metabolism could exert a cumulative effect on the risk of CVD.

Total PTX with forearm autograft transplantation remains the primary therapeutic means of addressing medication-refractory SHPT. A more recent investigation conducted by Sharma et al. (44) observed significantly reduced rates of all-cause and cardiovascular mortality in 150 dialysis patients who underwent near-total parathyroidectomy relative to 1044 non-PTX control patients. Accumulating evidence showed that successful PTX in severe SHPT patients led to substantial cardiovascular benefits, including improvement in BP (11,45), amelioration of uremic tumoral calcinosis (46,47), decrease in thickness of coronary artery intima media (10), and reduction in left ventricular mass index (48). However, whether successful PTX can affect cardiac autonomic outflow in severe SHPT remains unclear.

We then subjected 17 successful PTX patients to another 5.0 months of follow-up and observed a substantial correction of serum iPTH, Ca, P, and ALP and a significant increase in serum Alb (Figure 1). Improvements in HRV indices (mean HR, mean NN, SDNN, SDANN, VLF, HF, and LF/HF) (Table 4) indicated a decrease in sympathetic activity and an increase in parasympathetic activity. No significant changes of HRV were shown in patients after unsuccessful PTX (Table 4); however, the possibility of statistical error because of the small sample size and the short duration of follow-up demanded vigilance. The mechanisms by which successful PTX conferred benefits on HRV were not certain. The correction of mineral markers and serum Alb level may partially but crucially represent the impact of SHPT on HRV. Whether other factors contributed to the reversal of decreased HRV in these patients remained unknown. We also cannot exclude the possibility that PTX can improve HRV in cases of less severe SHPT. Sharma et al. (44) suggested that significantly corrected laboratory values, such as serum Alb, Hct, iPTH, Ca, and P, may have remarkable beneficial effects on cardiovascular outcomes. In our study, we speculate that the improvement of HRV may represent an important pathway linking PTX to better patient survival.

This study showed that successful PTX in severe SHPT patients could lead to amelioration of abnormal mineral metabolism and a relative physiologic sympathovagal balance. Patient selection during the follow-up study may have introduced some selection bias. However, there were no statistically significant differences between the successful PTX follow-up group and the nonfollow-up group. The lack of matched non-PTX controls was one limitation of the present study. Generally, severe SHPT patients can be scheduled for surgery shortly after they are confirmed refractory to medical therapy. Using untreated severe SHPT patients as controls during follow-up studies was not considered acceptable by medical ethicists. In the future, the longitudinal changes of HRV indices should be investigated in studies with larger sample sizes and longer observation periods.

Our data have shown a significant reduction in baseline HRV parameters in stage 5 CKD patients relative to age- and sex-matched controls. This result may reflect dysfunction of the cardiac autonomic nervous system as sympathetic hyperactivity. Disorders of mineral metabolism were correlated with decreased HRV in stage 5 CKD. Successful PTX in severe SHPT patients may contribute to reverse this high CVD risk by blunting sympathetic hyperactivity and enhancing parasympathetic activity as indicated by HRV parameters. Our research provides a novel insight into the mechanism linking PTX to CVD risk and the potential therapeutic avenue in severe SHPT patients.

Disclosures

None.

Acknowledgments

The authors thank Chengjing Yan and Qiaodi Zhang for assistance with the measurement of laboratory indices, Yun Xia, Zhihui Song, and Jing Tu for assistance with the analysis of heart rate variability, Feng Chen and Min Cai for assistance with statistical analyses, and Cuiping Liu for the management of blood samples.

This study was funded by National Natural Science Foundation of China (81270408), ZX07 200908, RC201162, 2010(IB10), and LJ201125, PAPD.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • Received October 9, 2012.
  • Accepted March 29, 2013.
  • Copyright © 2013 by the American Society of Nephrology

References

  1. ↵
    1. Collins AJ,
    2. Foley RN,
    3. Chavers B,
    4. Gilbertson D,
    5. Herzog C,
    6. Johansen K,
    7. Kasiske B,
    8. Kutner N,
    9. Liu J,
    10. St Peter W,
    11. Guo H,
    12. Gustafson S,
    13. Heubner B,
    14. Lamb K,
    15. Li S,
    16. Peng Y,
    17. Qiu Y,
    18. Roberts T,
    19. Skeans M,
    20. Snyder J,
    21. Solid C,
    22. Thompson B,
    23. Wang C,
    24. Weinhandl E,
    25. Zaun D,
    26. Arko C,
    27. Chen SC,
    28. Daniels F,
    29. Ebben J,
    30. Frazier E,
    31. Hanzlik C,
    32. Johnson R,
    33. Sheets D,
    34. Wang X,
    35. Forrest B,
    36. Constantini E,
    37. Everson S,
    38. Eggers P,
    39. Agodoa L
    : United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 59[1 Suppl 1]: e1–e420, 2012
    OpenUrlCrossRefPubMed
  2. ↵
    1. Goodman WG,
    2. Quarles LD
    : Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. Kidney Int 74: 276–288, 2008pmid:17568787
    OpenUrlCrossRefPubMed
    1. Cunningham J,
    2. Locatelli F,
    3. Rodriguez M
    : Secondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 6: 913–921, 2011pmid:21454719
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Moe S,
    2. Drüeke T,
    3. Cunningham J,
    4. Goodman W,
    5. Martin K,
    6. Olgaard K,
    7. Ott S,
    8. Sprague S,
    9. Lameire N,
    10. Eknoyan G,
    11. Kidney Disease: Improving Global Outcomes (KDIGO)
    : Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945–1953, 2006pmid:16641930
    OpenUrlCrossRefPubMed
  4. ↵
    1. Block GA,
    2. Klassen PS,
    3. Lazarus JM,
    4. Ofsthun N,
    5. Lowrie EG,
    6. Chertow GM
    : Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218, 2004pmid:15284307
    OpenUrlAbstract/FREE Full Text
    1. Kalantar-Zadeh K,
    2. Kuwae N,
    3. Regidor DL,
    4. Kovesdy CP,
    5. Kilpatrick RD,
    6. Shinaberger CS,
    7. McAllister CJ,
    8. Budoff MJ,
    9. Salusky IB,
    10. Kopple JD
    : Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771–780, 2006pmid:16820797
    OpenUrlCrossRefPubMed
    1. Moe SM,
    2. Drüeke TB
    : Management of secondary hyperparathyroidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 23: 369–379, 2003pmid:14551461
    OpenUrlCrossRefPubMed
  5. ↵
    1. Raggi P,
    2. Kleerekoper M
    : Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 836–843, 2008pmid:18322050
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Kestenbaum B,
    2. Andress DL,
    3. Schwartz SM,
    4. Gillen DL,
    5. Seliger SL,
    6. Jadav PR,
    7. Sherrard DJ,
    8. Stehman-Breen C
    : Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66: 2010–2016, 2004pmid:15496173
    OpenUrlCrossRefPubMed
  7. ↵
    1. Naranda J,
    2. Ekart R,
    3. Pečovnik-Balon B
    : Total parathyroidectomy with forearm autotransplantation as the treatment of choice for secondary hyperparathyroidism. J Int Med Res 39: 978–987, 2011pmid:21819732
    OpenUrlCrossRefPubMed
  8. ↵
    1. Coen G,
    2. Calabria S,
    3. Bellinghieri G,
    4. Pecchini F,
    5. Conte F,
    6. Chiappini MG,
    7. Ferrannini M,
    8. Lagona C,
    9. Mallamace A,
    10. Manni M,
    11. DiLuca M,
    12. Sardella D,
    13. Taggi F
    : Parathyroidectomy in chronic renal failure: Short- and long-term results on parathyroid function, blood pressure and anemia. Nephron 88: 149–155, 2001pmid:11399918
    OpenUrlCrossRefPubMed
  9. ↵
    1. Costa-Hong V,
    2. Jorgetti V,
    3. Gowdak LH,
    4. Moyses RM,
    5. Krieger EM,
    6. De Lima JJ
    : Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 142: 699–703, 2007pmid:17981190
    OpenUrlCrossRefPubMed
  10. ↵
    1. Chandra P,
    2. Sands RL,
    3. Gillespie BW,
    4. Levin NW,
    5. Kotanko P,
    6. Kiser M,
    7. Finkelstein F,
    8. Hinderliter A,
    9. Pop-Busui R,
    10. Rajagopalan S,
    11. Saran R
    : Predictors of heart rate variability and its prognostic significance in chronic kidney disease. Nephrol Dial Transplant 27: 700–709, 2012pmid:21765187
    OpenUrlCrossRefPubMed
    1. Battipaglia I,
    2. Scalone G,
    3. Macchione A,
    4. Pinnacchio G,
    5. Laurito M,
    6. Milo M,
    7. Pelargonio G,
    8. Bencardino G,
    9. Bellocci F,
    10. Pieroni M,
    11. Lanza GA,
    12. Crea F
    : Association of heart rate variability with arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ J 76: 618–623, 2012pmid:22260941
    OpenUrlCrossRefPubMed
  11. ↵
    1. Fukuta H,
    2. Hayano J,
    3. Ishihara S,
    4. Sakata S,
    5. Mukai S,
    6. Ohte N,
    7. Ojika K,
    8. Yagi K,
    9. Matsumoto H,
    10. Sohmiya S,
    11. Kimura G
    : Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant 18: 318–325, 2003pmid:12543887
    OpenUrlCrossRefPubMed
  12. ↵
    1. Oikawa K,
    2. Ishihara R,
    3. Maeda T,
    4. Yamaguchi K,
    5. Koike A,
    6. Kawaguchi H,
    7. Tabata Y,
    8. Murotani N,
    9. Itoh H
    : Prognostic value of heart rate variability in patients with renal failure on hemodialysis. Int J Cardiol 131: 370–377, 2009pmid:18199499
    OpenUrlCrossRefPubMed
  13. ↵
    1. Wei CY,
    2. Chung TC,
    3. Wu SC,
    4. Chung CF,
    5. Wu WP
    : The subjective sleep quality and heart rate variability in hemodialysis patients. Ren Fail 33: 109–117, 2011pmid:21332330
    OpenUrlCrossRefPubMed
    1. Chan CT,
    2. Levin NW,
    3. Chertow GM,
    4. Larive B,
    5. Schulman G,
    6. Kotanko P,
    7. Frequent Hemodialysis Network Daily Trial Group
    : Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol 5: 1821–1827, 2010pmid:20616163
    OpenUrlAbstract/FREE Full Text
    1. Chan CT,
    2. Hanly P,
    3. Gabor J,
    4. Picton P,
    5. Pierratos A,
    6. Floras JS
    : Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int 65: 661–665, 2004pmid:14717939
    OpenUrlCrossRefPubMed
  14. ↵
    1. Steinberg AA,
    2. Mars RL,
    3. Goldman DS,
    4. Percy RF
    : Effect of end-stage renal disease on decreased heart rate variability. Am J Cardiol 82: 1156–1158, 1998
    OpenUrlCrossRefPubMed
  15. ↵
    1. National Kidney Foundation
    : K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42[Suppl 3]: S1–S201, 2003pmid:14520607
    OpenUrlPubMed
  16. ↵
    1. Kojima M,
    2. Hayano J,
    3. Fukuta H,
    4. Sakata S,
    5. Mukai S,
    6. Ohte N,
    7. Seno H,
    8. Toriyama T,
    9. Kawahara H,
    10. Furukawa TA,
    11. Tokudome S
    : Loss of fractal heart rate dynamics in depressive hemodialysis patients. Psychosom Med 70: 177–185, 2008pmid:18256338
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Roumelioti ME,
    2. Ranpuria R,
    3. Hall M,
    4. Hotchkiss JR,
    5. Chan CT,
    6. Unruh ML,
    7. Argyropoulos C
    : Abnormal nocturnal heart rate variability response among chronic kidney disease and dialysis patients during wakefulness and sleep. Nephrol Dial Transplant 25: 3733–3741, 2010pmid:20466675
    OpenUrlCrossRefPubMed
  18. ↵
    1. Hayano J,
    2. Takahashi H,
    3. Toriyama T,
    4. Mukai S,
    5. Okada A,
    6. Sakata S,
    7. Yamada A,
    8. Ohte N,
    9. Kawahara H
    : Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Nephrol Dial Transplant 14: 1480–1488, 1999pmid:10383012
    OpenUrlCrossRefPubMed
  19. ↵
    1. Schroeder EB,
    2. Chambless LE,
    3. Liao D,
    4. Prineas RJ,
    5. Evans GW,
    6. Rosamond WD,
    7. Heiss G,
    8. Atherosclerosis Risk in Communities (ARIC) study
    : Diabetes, glucose, insulin, and heart rate variability: The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 28: 668–674, 2005pmid:15735206
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology
    : Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J 17: 354–381, 1996pmid:8737210
    OpenUrlCrossRefPubMed
  21. ↵
    1. Chan CT
    : Heart rate variability in patients with end-stage renal disease: An emerging predictive tool for sudden cardiac death? Nephrol Dial Transplant 23: 3061–3062, 2008pmid:18503010
    OpenUrlCrossRefPubMed
  22. ↵
    1. Ranpuria R,
    2. Hall M,
    3. Chan CT,
    4. Unruh M
    : Heart rate variability (HRV) in kidney failure: Measurement and consequences of reduced HRV. Nephrol Dial Transplant 23: 444–449, 2008pmid:18003665
    OpenUrlCrossRefPubMed
  23. ↵
    1. Yang YW,
    2. Wu CH,
    3. Tsai MK,
    4. Kuo TB,
    5. Yang CC,
    6. Lee PH
    : Heart rate variability during hemodialysis and following renal transplantation. Transplant Proc 42: 1637–1640, 2010pmid:20620490
    OpenUrlCrossRefPubMed
    1. Furuland H,
    2. Linde T,
    3. Englund A,
    4. Wikström B
    : Heart rate variability is decreased in chronic kidney disease but may improve with hemoglobin normalization. J Nephrol 21: 45–52, 2008pmid:18264936
    OpenUrlPubMed
    1. Giordano M,
    2. Manzella D,
    3. Paolisso G,
    4. Caliendo A,
    5. Varricchio M,
    6. Giordano C
    : Differences in heart rate variability parameters during the post-dialytic period in type II diabetic and non-diabetic ESRD patients. Nephrol Dial Transplant 16: 566–573, 2001pmid:11239033
    OpenUrlCrossRefPubMed
    1. Kurata C,
    2. Uehara A,
    3. Sugi T,
    4. Ishikawa A,
    5. Fujita K,
    6. Yonemura K,
    7. Hishida A,
    8. Ishikawa K,
    9. Tawarahara K,
    10. Shouda S,
    11. Mikami T
    : Cardiac autonomic neuropathy in patients with chronic renal failure on hemodialysis. Nephron 84: 312–319, 2000pmid:10754407
    OpenUrlCrossRefPubMed
  24. ↵
    1. Deligiannis A,
    2. Kouidi E,
    3. Tourkantonis A
    : Effects of physical training on heart rate variability in patients on hemodialysis. Am J Cardiol 84: 197–202, 1999pmid:10426340
    OpenUrlCrossRefPubMed
  25. ↵
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group
    : KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 113: S1–S130, 2009pmid:19644521
    OpenUrlPubMed
  26. ↵
    1. Martin KJ,
    2. González EA
    : Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: What is normal, when to start, and how to treat? Clin J Am Soc Nephrol 6: 440–446, 2011pmid:21292848
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Lishmanov A,
    2. Dorairajan S,
    3. Pak Y,
    4. Chaudhary K,
    5. Chockalingam A
    : Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol 44: 541–547, 2012pmid:21327525
    OpenUrlCrossRefPubMed
  28. ↵
    1. Nasri H,
    2. Baradaran A
    : Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. Bratisl Lek Listy (Tlacene Vyd) 105: 368–373, 2004pmid:15658577
    OpenUrlPubMed
  29. ↵
    1. Akmal M,
    2. Barndt RR,
    3. Ansari AN,
    4. Mohler JG,
    5. Massry SG
    : Excess PTH in CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int 47: 158–163, 1995pmid:7731141
    OpenUrlCrossRefPubMed
  30. ↵
    1. Grandi NC,
    2. Breitling LP,
    3. Hahmann H,
    4. Wüsten B,
    5. März W,
    6. Rothenbacher D,
    7. Brenner H
    : Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart 97: 1215–1221, 2011pmid:21586795
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Perkovic V,
    2. Hunt D,
    3. Griffin SV,
    4. du Plessis M,
    5. Becker GJ
    : Accelerated progression of calcific aortic stenosis in dialysis patients. Nephron Clin Pract 94: c40–c45, 2003pmid:12845236
    OpenUrlCrossRefPubMed
  32. ↵
    1. Peiris AN,
    2. Youssef D,
    3. Grant WB
    : Secondary hyperparathyroidism: Benign bystander or culpable contributor to adverse health outcomes? South Med J 105: 36–42, 2012pmid:22189665
    OpenUrlCrossRefPubMed
  33. ↵
    1. Wanic-Kossowska M,
    2. Guzik P,
    3. Lehman P,
    4. Czekalski S
    : Heart rate variability in patients with chronic renal failure treated by hemodialysis. Pol Arch Med Wewn 114: 855–861, 2005pmid:16708559
    OpenUrlPubMed
  34. ↵
    1. Polak G,
    2. Strózecki P,
    3. Grześk G,
    4. Manitius J,
    5. Grabczewska Z,
    6. Przybył R
    : Effect of parathormone on heart rate variability in hemodialysis patients. Auton Neurosci 115: 94–98, 2004pmid:15507410
    OpenUrlCrossRefPubMed
  35. ↵
    1. Sharma J,
    2. Raggi P,
    3. Kutner N,
    4. Bailey J,
    5. Zhang R,
    6. Huang Y,
    7. Herzog CA,
    8. Weber C
    : Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 214: 400–407, 2012pmid:22463880
    OpenUrlCrossRefPubMed
  36. ↵
    1. Evenepoel P,
    2. Claes K,
    3. Kuypers D,
    4. Maes B,
    5. Vanrenterghem Y
    : Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: A single centre study. Nephrol Dial Transplant 20: 1714–1720, 2005pmid:15919696
    OpenUrlCrossRefPubMed
  37. ↵
    1. Zouboulis CC,
    2. Blume-Peytavi U,
    3. Lennert T,
    4. Stavropoulos PG,
    5. Schwarz A,
    6. Runkel N,
    7. Trautmann C,
    8. Orfanos CE
    : Fulminant metastatic calcinosis with cutaneous necrosis in a child with end-stage renal disease and tertiary hyperparathyroidism. Br J Dermatol 135: 617–622, 1996pmid:8915159
    OpenUrlCrossRefPubMed
  38. ↵
    1. Goldsmith DJ,
    2. Covic A,
    3. Sambrook PA,
    4. Ackrill P
    : Vascular calcification in long-term haemodialysis patients in a single unit: A retrospective analysis. Nephron 77: 37–43, 1997pmid:9380236
    OpenUrlCrossRefPubMed
  39. ↵
    1. Chow KM,
    2. Szeto CC,
    3. Kum LC,
    4. Kwan BC,
    5. Fung TM,
    6. Wong TY,
    7. Leung CB,
    8. Li PK
    : Improved health-related quality of life and left ventricular hypertrophy among dialysis patients treated with parathyroidectomy. J Nephrol 16: 878–885, 2003pmid:14736016
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 8 (8)
Clinical Journal of the American Society of Nephrology
Vol. 8, Issue 8
August 07, 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Parathyroidectomy and Heart Rate Variability in Patients with Stage 5 CKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Parathyroidectomy and Heart Rate Variability in Patients with Stage 5 CKD
Jing Zhang, Xiangbao Yu, Bin Sun, Jianling Bai, Yongyue Wei, Xiaoming Zha, Yiyao Cui, Ming Zeng, Jingjing Zhang, Jia Liu, Huijuan Mao, Bo Zhang, Haibin Ren, Yifei Ge, Xueqiang Xu, Zhixiang Shen, Changying Xing, Kejiang Cao, Ningning Wang
CJASN Aug 2013, 8 (8) 1378-1387; DOI: 10.2215/CJN.10381012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Parathyroidectomy and Heart Rate Variability in Patients with Stage 5 CKD
Jing Zhang, Xiangbao Yu, Bin Sun, Jianling Bai, Yongyue Wei, Xiaoming Zha, Yiyao Cui, Ming Zeng, Jingjing Zhang, Jia Liu, Huijuan Mao, Bo Zhang, Haibin Ren, Yifei Ge, Xueqiang Xu, Zhixiang Shen, Changying Xing, Kejiang Cao, Ningning Wang
CJASN Aug 2013, 8 (8) 1378-1387; DOI: 10.2215/CJN.10381012
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Summary
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

Original Articles

  • Association of Polypharmacy with Kidney Disease Progression in Adults with CKD
  • The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function
  • Collectin11 and Complement Activation in IgA Nephropathy
Show more Original Articles

Mineral Metabolism/Bone Disease

  • Spine Trabecular Bone Score as an Indicator of Bone Microarchitecture at the Peripheral Skeleton in Kidney Transplant Recipients
  • Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial
  • Trabecular Bone Score and Incident Fragility Fracture Risk in Adults with Reduced Kidney Function
Show more Mineral Metabolism/Bone Disease

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire